Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792921 | 0.82 | KDM4E (0.44) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL14498848 | 0.77 | KDM4E (0.53) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL13058570 | 0.77 | KDM4E (0.40) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL19806261 | 0.71 | KDM4E (0.47) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL7819635 | 0.70 | HTR2C (0.41) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL24344559 | 0.68 | KDM4E (0.40) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL18806100 | 0.68 | DYRK1A (0.35) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL5333350 | 0.67 | KDM4E (0.50) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL13765829 | 0.67 | ICAM1 (0.45) | KDM4EMAPTALDH1A1HPGDPPARG | |
| SCHEMBL22504295 | 0.65 | KDM4E (0.42) | KDM4EMAPTALDH1A1HPGDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | KDM4E 1391/4885MAPT 4336/4885ALDH1A1 2693/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | KDM4E 1233/4885MAPT 4283/4885ALDH1A1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.